These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38065929)

  • 21. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
    Salman L; Martinez L; Faddoul G; Manning C; Ali K; Salman M; Vazquez-Padron R
    Kidney360; 2023 Jun; 4(6):e851-e860. PubMed ID: 37055910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.
    Wang N; Zhang C
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
    J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.
    Watanabe K; Sato E; Mishima E; Miyazaki M; Tanaka T
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.
    Luo X; Xu J; Zhou S; Xue C; Chen Z; Mao Z
    Clin J Am Soc Nephrol; 2023 Aug; 18(8):1019-1030. PubMed ID: 37256921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mineralocorticoid receptor in chronic kidney disease.
    Barrera-Chimal J; Jaisser F; Anders HJ
    Br J Pharmacol; 2022 Jul; 179(13):3152-3164. PubMed ID: 34786690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
    Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
    Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.
    Tuttle KR; Wong L; St Peter W; Roberts G; Rangaswami J; Mottl A; Kliger AS; Harris RC; Gee PO; Fowler K; Cherney D; Brosius FC; Argyropoulos C; Quaggin SE;
    Clin J Am Soc Nephrol; 2022 Jul; 17(7):1092-1103. PubMed ID: 35649722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
    Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS
    Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
    Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
    Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
    DeFronzo RA; Bakris GL
    Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.